A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

NCT04429087 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Interventions

DRUG: Obrixtamig - parenteral 1
DRUG: Obrixtamig - parenteral 2

Sponsor

Boehringer Ingelheim